Skip to content
Head to head

CG Oncology vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: CGON · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

CGON +92.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
CGONVRTX
Snapshot
Sector--Biotechnology
Last price79.47515.02
Change today-2.97%-1.08%
1-year return+95.2%+22.0%
Market cap$7.10B$130.58B
52-week range37.01 – 93.95412.27 – 568.67
Valuation
P/E (TTM)-28.7933.14
P/E percentile, own 5-yr range47th99th
P/B7.166.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.0815.32
Net profit (TTM)$-185.78M$3.88B
Revenue (TTM)$6.17M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-3.7%+11.8%
Gross margin-104.8%85.5%
Operating margin-4293.5%33.1%
Net margin-3851.1%30.7%
Free cash flow (TTM)$-189.17M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership116.2%96.8%
Insider activity (12mo)15 buy / 35 sell28 buy / 22 sell
Short interest (% of float)10.4%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$90 (+13%)$624 (+21%)
StockVane view
StockVane Quant RatingC (96)C (68)
Company
Employees1426,400
Founded20101989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.